Portfolio
Explore select Tachyon portfolio companies.
Companies advancing target biology, molecular design and delivery, alongside opportunities in diagnostics and bioengineering.
Filter
All
Target
Molecule
Delivery
Bioengineering
Exited
Stylus Medicine
Editing genes inside the body, no cell extraction required.
Delivery · in vivo
→
AI Proteins
ExitedTiny proteins designed from scratch, not fished out of a library.
Molecule · design
→
Mirecule
RNA medicines that reach muscle, not just the liver.
Delivery · RNA
→
Haima Therapeutics
Platelet-inspired therapies for bleeding that won't stop.
Molecule · platform
→
Palm Therapeutics
Going after palmitoylation, starting with cancer.
Target · oncology
→
EpiBone
Personalized bone grafts grown from a patient's own stem cells.
Bioengineering · tissue
→
Peptilogics
New peptide antibiotics, designed fast.
Molecule · peptides
→
Axonis Therapeutics
Starting from human genetics to find neuro targets that hold up.
Target · neuro
→
Altay Therapeutics
Drugging transcription factors directly.
Target · transcription
→
Totient
Acquired by AbsciHigh-throughput antibody discovery.
Molecule · antibodies
→
DTx Pharma
Acquired by NovartissiRNA delivery that lets you choose the target.
Delivery · siRNA
→
Forkhead
Teaching gut cells to make insulin.
Target · metabolic
Scipher Medicine
Tests that predict who a drug will actually work for.
Diagnostics · precision
→
Mammoth Biosciences
Taking CRISPR from a lab tool to actual medicines.
Target · editing
→
Quthero
Getting skin to heal itself, properly.
Bioengineering · wound
→
TARA
ExitedLab-grown heart tissue that behaves like the real thing.
Bioengineering · cardiac
→
Enclear Therapies
Clearing the toxic proteins that build up in the brain and spinal cord.
Delivery · CNS
→
Chameleon Biosciences
Making AAV gene therapies land where they should.
Delivery · AAV
→
secondaries
The companies above are our venture investments. Positions acquired through Secondaries are confidential and not disclosed.
Get in touch
Building a biotech company or selling a fund interest?
Tell us about the company you're building, or talk to us about selling or transferring a biotech fund interest.